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ABSTRACT
Objectives To assess the diagnostic accuracy and clinical
utility of a simplified low cost method for measuring
absolute and percentage CD4 counts with flow cytometry.
Design A CD4 counting method (Blantyre count) using a
CD4 and CD45 antibody combination with reduced blood
and reagent volumes. Diagnostic accuracy was assessed
by measuring agreement of the index test with two other
assays (TruCount and FACSCount). Clinical utility was
investigated by comparing CD4 counts with the new assay
with WHO clinical staging in patients with HIV.
Setting Research laboratories and antiretroviral therapy
clinic at a medical school and large government hospital
in southern Malawi.
Participants Assay comparisons were performed on
consecutive blood samples sent for CD4 counting from
129 patients with HIV. Comparison of CD4 count with
staging was conducted on 253 consecutive new patients
attending the antiretroviral therapy clinic.
Main outcome measures Limits of agreement with 95%
confidence intervals between index test and reference
standards.
Results The limits of agreement for Blantyre count and
TruCount were excellent (cell count −48.9 to 27.0 cells/µl
for absolute counts in the CD4 range <400 cells/µl and
−2.42% to 2.37% for CD4 percentage). The assay was
affordable with reagent costs per test of $0.44 (£0.22,
€0.33) for both absolute count and CD4 percentage, and
$0.11 for CD4 percentage alone. Of 193 patients with
clinical stage I or II disease, who were ineligible for
antiretroviral therapy by clinical staging criteria, 73 (38%)
had CD4 counts <200 cells/µl. By contrast, 12 (20%) of 60
patients with stage III or IV disease had CD4 counts >350
cells/µl.
Conclusions This simplifiedmethod of counting CD4 cells
with flow cytometry has good agreement with established
commercial assays, is affordable for routine clinical use in
Africa, and could improve clinical decision making in
patients with HIV.
INTRODUCTION
InMalawi, a subSaharan African country with a popu-
lation of 12 million, an estimated million people are
infected with HIV.1 In 2004 the Ministry of Health
embarked on an ambitious antiretroviral therapy pro-
gramme. By the end of March 2007, 95 674 patients
had started free antiretroviral therapy in public sector
clinics,2 largely on the basis of a clinical diagnosis of
WHO stage III or stage IV HIV/AIDS.3 Clinical
events, however, do not fully predict immunological
status.4 When clinical criteria alone are used, some
patients with stage I and stage II disease and severe
immune suppression will not receive the treatment
they need, while others with stage III and IV disease
may still have high CD4 T cell counts and the start of
antiretroviral therapy might be delayed.5
CD4 counting could therefore improve appropriate
allocation of antiretroviral therapy.6 Despite initiatives
by the Clinton Foundation and others to reduce the
price of the necessary reagents for developing nations
to $3-6 (£1.5-3.0; €2.2-4.4) per test,7 this cost is still high
for Africa.8 CD4 counting with flow cytometry is per-
ceivedbymany tobe too complex for use inAfrica. For
these reasons,CD4 counts are not routinely performed
in Malawi.9 WHO guidelines state that where CD4
counting is available, adults and children over 5 years
with HIV should start antiretroviral therapy as soon as
their CD4 counts drop below 200 cells/µl, regardless
of clinical staging.3 In children under 5 years, CD4per-
centage of total lymphocyte count (CD4 percentage)
varies less than absolute counts with age10 and so the
percentage value is recommended to help decide on
initiation of antiretroviral therapy.11
There are two main approaches for making CD4
counting more widely available in Africa: firstly, to
reduce the cost of and simplify flow cytometric CD4
counting, and, secondly, to develop alternative count-
ing methods. Flow cytometry, however, is the ideal
method and has high accuracy.612 High throughput is
possible as about 250 samples a day can be processed.8
Effective external quality assurance schemes are
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available in Africa with NEQAS (United Kingdom
national external quality assessment scheme)13 and
WHO CD4 REQAS/QASI (regional external quality
assurance scheme/quality assessment and standardisa-
tion for immunological measures relevant to HIV/
AIDS programme).14 Finally, flow cytometers can
measure CD4 percentage as well as absolute counts.
The main disadvantages are that flow cytometers are
expensive and complex, reagent costs are high, and
skilled laboratory staff are required.
Alternative counting methods include enzyme
linked immunosorbent assays (ELISA),15 dried whole
blood spots,16 lymphocyte rosetting,17 and magnetic
beads.18 Such methods do not require complex equip-
ment or the same level of staff training. The major dis-
advantage of such methods is poor ability to
discriminate between CD4 T cells and monocytes,
which also express CD4,19 low throughput, and poor
ability to determine CD4 percentage. Reagent costs
are similar to those of flow cytometric methods.8
Over recent years several technological develop-
ments have shown that flow cytometric CD4 counting
could be more straightforward. “Primary CD4 gating”
uses just one antibody against CD4 and side scattered
light to discriminate between lymphocytes and
monocytes.20 21 Gating of lymphocytes by using
CD45 expression and side scattered light is more accu-
rate and reproducible than using light scatter charac-
teristics alone.22 23 Recently, CD45 has been used to
gate all leucocytes on dual platforms, using a flow cyt-
ometer for CD4 percentage and a haematological ana-
lyser for absolute leucocyte counts.24 This
“panleucogating” strategy has beenmodified for single
platforms (flow cytometer alone) but remains primar-
ily focused on total leucocytes rather than on lympho-
cytes.
We investigated whether these technologies could
be miniaturised to reduce costs and applied them to
the FACSCalibur flow cytometer.We developed a sin-
gle platformmethod (the Blantyre count) that could be
performed with reduced reagent costs and could accu-
rately determine both absolute and percentage CD4
with increased simplicity compared with existing flow
cytometric methods. We compared our method with
the existing TruCount and FACSCountCD4 counting
assays for diagnostic accuracy and assessed the poten-
tial impact on clinical decision making.
METHODS
Setting
The study was conducted at the Malawi-Liverpool-
Wellcome Trust Research Programme andQueen Eli-
zabeth Central Hospital in Blantyre, the largest city in
the southern region of Malawi. The estimated preva-
lence of HIV infection among adults in Blantyre dis-
trict is 22%.25 All participants gave informed consent
for CD4 counting.
Instrumentation
We used a FACSCalibur flow cytometer, a FACS-
Count instrument (both Becton Dickinson, CA,
USA), and HmX haematological analyser (Beckman
Coulter, CA, USA). We analysed flow cytometric
data with CellQuest and MultiSet software.
Reference standards (TruCount and FACSCount assays)
We used TruCount26 and FACSCount27 assays for
CD4 counts usingMultitestCD3/8/45/4 kits withTru-
Count tubes and FACSCount reagent kits (Becton
Dickinson) according to the manufacturer’s instruc-
tions. TruCount assays use four antibodies, a complex
subgating strategy, and tubes containing pre-pipetted
beads. We chose TruCount as the reference standard
because it is a commercial CD4 counting method that
was developed to be used on the same instrument as
the index test (Becton Dickinson FACSCalibur flow
cytometer) and generates both absolute and percen-
tage CD4.We used FACSCount as a second reference
standard because it is one of themost widely usedCD4
counting technologies in Africa. Both TruCount and
FACSCount generate CD4 counts on a single plat-
form, although FACSCount requires a lymphocyte
count from a haematological analyser to generate
CD4 percentage. Both assays are used by clinical
laboratories throughout the world and have been vali-
dated by consistently high performance in external
quality assurance schemes such as UK NEQAS13
over a period of years.
Index test (Blantyre count assay)
We used venous blood from healthy adults anti-
coagulated with EDTA to develop our assay. We
used antihuman CD4 antibody conjugated with phy-
coerythrin (CD4-PE) and antihuman CD45 antibody
conjugated with fluorescein isothiocyanate (CD45-
FITC), FACS lysing solution (all Becton Dickinson),
and CytoCount fluorescent microbeads (Dako, Den-
mark). Adjustable air-diplacement pipettes (Pipetman;
Gilson, France) were used for all pipetting steps. The
same pipette was used for reverse pipetting of blood
and counting beads. CD4 T cell counts and total
lymphocyte populations were determined by using
staining for CD4 and CD45 with no attempt to gate
total leucocytes or total T cells. We mixed 20 µl
whole blood with 0.5 µl CD4-PE and 0.5 µl CD45-
FITC antibodies and incubated samples for
15 minutes in the dark at room temperature. Red
cells were lysedwith 180 µl of 1× FACS lysing solution
and incubated for a further 10minutes.We added 10µl
of CytoCount beads by reverse pipetting beforewe ran
samples through the cytometer.Weused reverse pipet-
ting for pipetting blood and counting beads as precise
volumes are critical and this method is more accurate
than conventional pipetting.12 Pipette calibration and
pipetting accuracy were assessed by dispensing 10 µl
and 20 µl aliquots of water on to a scientific balance.
Bead events, 2000 per sample over about
60 seconds, were acquired by using a live gate with
acquisition threshold set on the FL1 (FITC) channel.
Analysis was performed with a CD4-PE against side
scatter dot plot with manual gating of the CD4 T cell
population (R1) and counting beads (R2) (fig 1 top) and
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a separate side scatter againstCD45-FITCcontour plot
for manual gating of the total lymphocyte population
(R3) (fig 1 bottom).
We calculated absolute CD4 counts (cells/µl) with
the formula: (CD4 T cell events (R1)/bead events
(R2))×([bead solution] (beads/µl)/2).
We calculated CD4 percentage with the formula:
(CD4Tcell events (R1)/lymphocyte events (R3))×100.
We assessed repeatability of our assay by perform-
ing five repeats of the assay on four blood samples and
examined stability of results with time by leaving a
blood sample in the laboratory at room temperature
and performing five repeats of the assay daily on the
sample over five days.
Modified Blantyre count assays
We modified our assay to reduce costs further when
only an absolute or percentage CD4 is required. The
absolute CD4 count alone variant used CD4-PE anti-
body plus beads but without CD45-FITC antibody
(Blantyre count (absolute)). The variant giving the
CD4 percentage alone used CD4 and CD45 anti-
bodies without counting beads (Blantyre count (per-
centage)).
CD4 counting comparison studies
In the main CD4 counting comparison study we
included consecutive blood samples from patients
with HIV sent to our laboratory for full blood count
and CD4 count determination from 27 January to 17
February and from 18 April to 9 May 2006 (n=134).
WemeasuredCD4 andCD4 percentage for each sam-
ple using Blantyre count, Blantyre count (absolute),
TruCount, and FACSCount assays.
We carried out a subsequent smaller study on con-
secutive blood samples from patients with HIV sent to
the laboratory in June 2006 to compare CD4 percen-
tages generated by Blantyre count and Blantyre count
(percentage) assays (n=28). Samples were not used if
they exhibited clots, were sent fromoutsideQueenEli-
zabethCentral Hospital, or were received after the day
of blood collection or if insufficient bloodwas available
to complete all tests. There were no other selection cri-
teria. Blood sampleswere analysedon theday that they
were taken unless they were received after 4 pm in
which case they were processed the next morning.
Data collection was planned before the index tests
and reference standards were performed. All blood
samples from all participantsmeeting the inclusion cri-
teria underwent the index and reference standard tests.
No adverse events occurred from performing these
tests.
Two authors (FS and JB) performed and read the
FACSCount assay and full blood count. Two other
authors (MKPL and CAM), both of whom had pre-
vious experience of flow cytometry, performed and
read TruCount and Blantyre count assays together
within six hours of the FACSCount assay. We have
subsequently trained local laboratory technicians
over two to three days to perform the Blantyre count
method. Manual gating of events acquired with Blan-
tyre count was performed blind to other results. As the
FACSCount does not giveCD4percentages, we calcu-
lated this from the FACSCount absolute CD4 count
and total lymphocyte count from the haematological
analyser using the formula (CD4 (cells/µl)/total
lymphocyte count (cells/µl))×100. This procedure is
prone to error because CD4 percentage is generated
on a dual platform setting, which is inherently more
variable than single platform operations. For absolute
CD4 counts, we assessed agreement only for samples
with a TruCount CD4 count below 400 cells/µl as this
is the relevant range for clinical decision making. For
comparisons of CD4 percentage we used all samples.
Clinical utility study
We tested a further 253 EDTA anticoagulated venous
blood samples from new patients attending the adult
antiretroviral therapy clinic from May to July and
from September to October 2006 for CD4 count
using Blantyre count. CD4 counts and clinical staging
were compared for each patient. Clinical staff in the
CD45-FITC
S
id
e 
sc
at
te
r
0 10 100 1000 10 000
0
200
400
600
800
1000
CD4-PE
S
id
e 
sc
at
te
r
0 10 100 1000 10 000
0
200
400
600
800
1000
Fig 1 | Gating strategies for determining absolute and
percentage CD4 counts from flow cytometric data acquired
with Blantyre count. R1=CD4 positive T lymphocytes,
R2=CytoCount fluorescent microbeads, R3=total
lymphocytes, M=monocytes, N=neutrophils, L=CD4 negative
lymphocytes. Plots are for data acquired from same blood
sample with CD4 count=199 cells/µl and CD4 percentage
17.6% with Blantyre count assay. Top: dot plot of side
scattered light against CD4-PE (phycoerythrin). Absolute CD4
count=(R1/R2)×([beads] (beads/µl)/2); bottom: contour plot
of side scattered light against CD45-FITC (fluorescein
isothiocyanate). CD4 percentage=(R1 (from top)/R3)×100
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antiretroviral therapy clinic performed staging blind to
CD4 count results.
External quality assurance
To determine the accuracy of Blantyre count, we
enrolled the assay for external quality assurance with
the NEQAS immune monitoring scheme.13 CD4
results were determined on six NEQAS stabilised
blood samples from the UK between January and
May 2006.
Statistical analysis
We examined agreement between each pair of meth-
ods using Stata 9 by estimating bias and limits of agree-
ment (=bias plus or minus 1.96×SD) with 95%
confidence intervals as described by Bland and
Altman.28 Repeatability was assessed with coefficients
of variation obtained from five repeats of assays.
RESULTS
Refinement of Blantyre count
With 20, 10, 5, 2, and 1µl of control blood per Blantyre
count assay, coefficients of variation were 4.2%, 4.2%,
6.1%, 8.1%, and 10.7%, respectively, showing a pro-
gressive increase in coefficients of variation below 10
µl of blood. There was a decrease in mean absolute
CD4 count as blood volume was reduced (712, 681,
645, 539, and 448 cells/µl, respectively). CD4 percen-
tages showed better overall repeatability (coefficients
of variation 2.8% with 20 µl blood) and the coefficient
of variation did not noticeably increase until blood
volume was reduced to 2 µl (4.8%). We used 20 µl
blood for our assay as twice the lowest volume at
which optimal assay repeatability was maintained.
We used a similar process to determine optimal
counting bead volume. With 10 µl counting beads the
coefficient of variation was 4.2%, and similarly with 5
µl beads (4.3%), but increased to 8.9% and 5.7% with 2
and 1 µl beads, respectively. Mean CD4 counts were
not affected by bead volume. We used 10 µl counting
beads for our assay. Finally, we titrated down the quan-
tities of antibody per assay. Discrimination of CD4 T
cell and total lymphocytes as discrete populations was
still possible down to 0.25 µl of CD4-PE and 0.25 µl
CD45-FITC.We chose 0.5 µl of each antibody for use
in our assay. Using these quantities, the costs of
reagents per assay were $0.44 (£0.22, €0.33) for both
absolute and percentage counts, $0.40 for an absolute
CD4 count, and $0.11 for CD4 percentage alone
(table 1).
Characteristics of patients
In agreement studieswe testedblood samples from130
patients with HIV. One sample gave an absolute CD4
count >2000 cells/µl with FACSCount and was
excluded from subsequent analyses. There were no
indeterminate or missing results. The median age of
patients was 33 years (range 2-75 years); 79 were
females; and 38 (29%) were taking antiretroviral ther-
apy at the time of testing. Of the 253 new patients for
whom CD4 count was compared with clinical staging
in the antiretroviral therapy clinic, the median age was
33 (range 14-71), and 173 were female. None was tak-
ing antiretroviral therapy. We used a subset of 28 of
these patients for the separate comparison of Blantyre
count with the Blantyre count (percentage) variant.
The median age in this subset was 35 years (range
24-64 years), and 18 were female.
Absolute CD4 counts in agreement studies
ThemedianCD4 count was 193 cells/µl (range 0-1884
cells/µl) with TruCount. The mean bias when we used
Blantyre count rather than TruCount for samples with
a CD4 count of <400 cells/µl was −11.0 cells/µl for
Blantyre count. Similarly, low biases were found for
other assay comparisons: 1.2 cells/µl for FACSCount
comparedwithTruCount, and 5.8 cells/µl for Blantyre
count (absolute) compared with Blantyre count
(table 2). Limits of agreement were −48.9 to 27.0
cells/µl for Blantyre count and TruCount and were
within the range −55 to 40 cells/µl for all other assay
comparisons (table 2, fig 2).
CD4 percentage in agreement studies
The median CD4 percentage was 13.0% (range 0.0-
44.0%) using TruCount. Agreement between CD4
percentage generated by Blantyre count and Tru-
Count was excellent over the full range of values,
with a bias of −0.03% and limits of agreement −2.42%
to 2.37%. Comparison of either Blantyre count or Tru-
Count CD4 percentage with values generated using
FACSCount showed poorer agreement, with a bias of
Table 1 | Reagent costs per assaywith flow cytometry for counting CD4cells. Costs calculatedwithprices available tous in $ for all
reagents
CD4 assay
CD4-PE
antibody
CD45-FITC
antibody
Red cell lysing
solution
Fluorescent
beads* Kit Total
Blantyre count:
Absolute and percentage 0.056 0.042 0.014 0.329 0.44
Absolute 0.056 — 0.014 0.329 — 0.40
Percentage 0.056 0.042 0.014 — — 0.11
TruCount (Multitest) (absolute and percentage) — — 0.036† — 5.00 5.04
FACSCount (absolute) — — — — 6.00 6.00
CD4-PE=phycoerythrin conjugated antihuman CD4 antibody; CD4-FITC=fluorescein isothiocyanate conjugated antihuman CD45 antibody.
*Allowing for 12 µl/assay with reverse pipetting.
†Not provided with kit; 450 µl of 1× lysing solution required/assay.
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0.92% and limits of agreement −5.83% to 7.66% for
FACSCount and TruCount and a bias of −0.94% and
limits of agreement −7.56% to 5.67% for Blantyre
count and FACSCount. Blantyre count and the Blan-
tyre count (percentage) variant could be used inter-
changeably for CD4 percentage with excellent limits
of agreements (table 2, fig 2).
Repeatability of Blantyre count
We calculated coefficients of variation on five repeats
of our assay on four blood samples with mean CD4
values 718, 712, 260, and 191 cells/µl and mean CD4
percentage 40.3%, 42.9%, 15.0%, and 13.8%. Mean
(SD) coefficients of variation were 5.2% (2.7%) for
absolute CD4 count and 2.5% (0.8%) for CD4 percen-
tage.
Accuracy of Blantyre count
In tests on six stabilised blood samples (CD4 count
117-1269 cells/µl and percentage 7.28%-60.73%)
from NEQAS with our assay, five of six absolute
CD4 counts and five of six CD4 percentages were
within 1 SD of the NEQAS value, with one result of
six between 1 and 2 SD of this value for each test.
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Fig 2 | Comparison of CD4 counts determined with three flow cytometric methods using 96 blood samples from patients with
HIV with CD4 counts <400 cells/µl for absolute CD4 cell counts (cells/µl) and 129 blood samples for CD4 cell counts as a
percentage of total lymphocyte count (CD4 percentage). FACSCount CD4 percentage was obtained from FACSCount absolute
CD4 counts and total lymphocyte counts from a haematological analyser. Black lines depict bias and upper and lower limits of
agreement. Grey broken lines denote 95% confidence intervals for these values
Table 2 | Estimated bias and limits of agreement, with 95%confidence intervals for pairs of flow cytometricmethods used to
measure absolute and percentage CD4 cell counts
Assay comparison Bias (95% CI)
Limits of agreement
Lower limit (95% CI) Upper limit (95% CI)
Absolute CD4 (cells/µl)
Blantyre count and TruCount −11.0 (−14.9 to −7.1) −48.9 (−55.7 to −42.1) 27.0 (20.2 to 33.8)
FACSCount and TruCount 1.2 (−2.6 to 4.9) −35.4 (−41.9 to −28.8) 37.7 (31.2 to 44.3)
Blantyre count and FACSCount −12.1 (−16.6 to −7.7) −54.8 (−62.4 to −47.1) 30.5 (22.8 to 38.1)
Blantyre count and Blantyre count (absolute) −5.8 (−9.3 to −2.3) −39.3 (−45.3 to −33.3) 27.7 (21.7 to 33.7)
CD4 percentage
Blantyre count and TruCount −0.03 (−0.24 to 0.19) −2.42 (−2.78 to −2.05) 2.37 (2.00 to 2.73)
FACSCount* and TruCount 0.92 (0.32 to 1.52) −5.83 (−6.87 to −4.79) 7.66 (6.62 to 8.70)
Blantyre count and FACSCount* −0.94 (−1.53 to −0.35) −7.56 (−8.57 to −6.54) 5.67 (4.66 to 6.69)
Blantyre count and Blantyre count
(percentage)
0.01 (−0.26 to 0.28) −1.35 (−1.82 to −0.88) 1.37 (0.90 to 1.84)
*CD4 percentages with FACSCount calculated from absolute CD4 count by FACSCount and total lymphocyte count from haematological analyser.
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Blantyre count values were on average 95% of the
absolute NEQASCD4 count and 97% of the CD4 per-
centage.
Stability of aged samples
CD4 T cell and lymphocyte populations could be
clearly distinguished and gated over the five days of
the stability study, with a blood sample with day 1
CD4 count of 487 cells/µl and CD4 percentage of
36.1%. Daily coefficients of variation for absolute
counts remained below 6% and for CD4 percentage
below 2.5%. The mean absolute CD4 count stayed
within 10% and the CD4 percentage within 5% of the
day 1 values.
Clinical staging and CD4 counts for new patients attending
antiretroviral therapy clinic
Of the new patients attending the antiretroviral ther-
apy clinic, 76% (193/253) were clinical stage I (n=77)
or stage II (n=116), while 24% (60/253) had stage III
(n=51) or stage IV (n=9) HIV/AIDS. The range of
CD4 counts in each group was wide with a progressive
fall inmedianCD4 counts from stage I (286 cells/µl) to
stage IV groups (110 cells/µl). Twenty five (32%)
patients with stage I disease and 48 (42%) with stage
II disease had a CD4 count <200 cells/µl. Eleven
(22%) patients with stage III and one (11%) patient
with stage IV HIV/AIDS had a CD4 count >350
cells/µl (table 3).
DISCUSSION
WithinMalawi,wehavedevelopedan affordable accu-
ratemethodof countingCD4cells with flow cytometry
by refining and miniaturising existing technology.
Increasing affordability by reducing reagent costs is a
critical step in making this available in countries with
limited resources. Currently the reagent cost of a com-
parable commercially available flow cytometric assay
in Africa is $5.04 (£2.52, €3.74). As we were able to
reduce costs of reagents to $0.44 (£0.22, €0.33) per
assay, there is the potential for 91% cost savings. This
would increase to 98% if only CD4 percentage is
required but would decrease if the costs of competing
tests are reduced.
Cost reduction was not achieved at the expense of
accuracy. Over the CD4 count range of 0-400 cells/
µl, our assay showedminimal bias and excellent agree-
ment compared with established CD4 counting meth-
ods (TruCount and FACSCount). Determination of
CD4 percentage by Blantyre count and TruCount
methods showed excellent agreement over the full
range of CD4 percentages. The good performance of
Blantyre count in the NEQAS immunophenotyping
scheme further shows the accuracy of this method.
Aswell as reducing the assayprice, themodifications
in our assay have simplified CD4 counting with flow
cytometry. Use of a primary CD4 gating strategy
avoids extra sub-gating steps involving the CD3 or
CD45 cell populations as performed by other estab-
lished methods, including TruCount/Multitest and
Panleucogating technologies.24 26 It has proved
straightforward to train technicians to gate the CD4 T
cells (R1), counting beads (R2), and total lymphocyte
populations (R3) using CD4/side scatter and CD45/
side scatter dot plots (fig 1).
Strengths and weakness of study
Our study validates the use of a simplified, affordable,
and accurate method of CD4 counting with flow cyto-
metry. Unlike many previous studies of affordable
flow cytometry,20-22 24 we carried out this work in a
country where affordability is of chief importance.
We looked at both absolute and percentage CD4,
which have previously been neglected. The limits of
agreement are similar to those of previous comparison
studies of flow cytometry and narrower than studies
using other methods,15-18 which are inherently less
accurate. By miniaturising the present assay, we man-
aged to reduce reagent costs further compared with
previous studies.
Even with the simplifications introduced, however,
CD4 counting with flow cytometry requires a level of
technical skill not always present in resource poor
settings,9 a reliable power supply, and a cold chain for
reagent supplies. A flow cytometer represents a large
capital outlay, which is not always feasible, although
donor funding is sometimes available to help provide
such instruments.
Users of FACSCount and other methods that pro-
vide only the absolute CD4 count have needed to use
total lymphocyte counts (usually from haematological
analysers) to obtain the CD4 percentage. The poor
agreement betweenCD4percentage obtained by com-
bined FACSCount plus haematological analysis when
compared with CD4 percentage produced by either
Blantyre count or TruCount (table 2, fig 2) shows the
inaccuracy of this laborious “reversed dual platform”
approach. It is well recognised that flow cytometers
Table 3 | Comparison of clinical stagingwith absolute CD4 count withBlantyre count for newpatients seen at antiretroviral clinic
Clinical stage No (%) of patients Median (range) CD4 cells/µl
No (%) with CD4 cells/µl
<200 200-350 >350
I 77 (30) 286 (20-1020) 25 (32) 25 (32) 27 (35)
II 116 (46) 249 (4-1261) 48 (42) 41 (35) 27 (23)
III 51 (20) 149 (11-826) 29 (57) 11 (22) 11 (22)
IV 9 (4) 110 (16-552) 7 (78) 1 (11) 1 (11)
All 253 239 (4-1261) 110 (43) 78 (31) 65 (26)
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and haematological analysers can produce signifi-
cantly different total lymphocyte counts for the same
blood sample.12 24
The excellent agreement between Blantyre count
and TruCount assays indicates that use of CD3 anti-
body by TruCount is redundant in CD4 counting
with flow cytometry. This means that Blantyre count
technology could be operated on less complex instru-
ments than the FACSCalibur, deployingonly one laser
and three photomultiplier tubes to detect side scattered
light and fluorescence emitted from FITC and PE
fluorochromes. Such an instrument could bemanufac-
tured at lower cost compared with the FACSCalibur
and would be simpler and less expensive to maintain.
Evenon five dayold blood, our gating strategy enabled
both CD4 T cells and lymphocytes to be easily discri-
minated from monocytes, thereby maintaining good
repeatabilitywith little variability fromdayone counts.
Blantyre count could make the greatest impact on
the care of children under 5 with HIV. Appropriate
determination of CD4 percentage has often been
neglected by investigators seeking to produce afford-
able CD4 counting.68 Determination of CD4 percen-
tage alone by the Blantyre count (percentage) variant is
not only much cheaper than determining absolute
CD4 counts but also technically easier, as accurate
volumetric pipetting and counting beads are not
required. CD4 percentages were also more stable
than absolute counts over five days in the same sample.
The determination of CD4 counts with Blantyre
count in the antiretroviral therapy clinic confirms that
use ofWHO clinical staging criteria alone for deciding
who should start antiretroviral therapy is suboptimal.
About a third of patients with clinical stage I or II dis-
ease who would not be eligible for antiretroviral ther-
apy on clinical grounds were severely
immunosuppressed with a CD4 count of <200 cells/
µl. Conversely, two fifths of patients with stage III
and IV disease who were eligible to start antiretroviral
therapy had CD4 counts >200 cells/µl and a fifth had
counts >350 cells/µl. Clinical staging alone is missing
many patients who urgently need to start antiretroviral
therapy, while some stage III and IV patients are
started on antiretroviral therapy when treatment
could possibly be postponed.
What would it cost?
Consideration of the economic feasibility of using the
Blantyre count inMalawi has to include the capital cost
of the flow cytometer (about $100 000), the annual ser-
vice contract (about $10 000), and the salary of a
laboratory technician (typical monthly salary $500)
as well as reagent prices. The contribution of these
non-reagent costs to the total cost per assay is inversely
proportional to assay throughput.With the cost of such
an instrument spread over 10 years, CD4 counting
with flow cytometry would not be viable if only 200
samples were run on an instrument each month, as
“non-reagent costs” per sample would be $10.83. If,
however, 200 samples are run on a flow cytometer
eachday,which iswell within the capacity of the instru-
ment (over 250 days this would be 50 000 samples a
year), non-reagent costs are $0.52 per sample, giving
a total assay cost of $0.96. Therefore, use of the Blan-
tyre count method would be most cost effective with a
limited number of flow cytometers operating at high
sample throughput in regional centres and a coordi-
nated system for transporting samples to these centres
from peripheral clinics.
Wehave described an affordable accuratemethod of
CD4 counting that has the potential to improve clinical
decision making in the treatment of patients with HIV
and service the whole of a country the size of Malawi
using a limited number of instruments in regional cen-
tres. This arrangement could be facilitated by the use of
blood stabilising agents such as Transfix, permitting
delays in sending samples to regional centres.29 It
remains to be seen whether such a service could be
successfully implemented in such a resource poor set-
ting.
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